Biocon Biologics Bolstered By Goldman Sachs Investment
Deal Worth $150m Values Biocon Subsidiary At Nearly $4bn
Executive Summary
Goldman Sachs is investing around $150m in Biocon Biologics, valuing the Biocon subsidiary at just under $4bn.
You may also be interested in...
Biocon Biologics Garners $75m ADQ Investment
Biocon has secured the latest in a series of investments in its Biocon Biologics subsidiary, from Abu Dhabi based ADQ. The transaction, worth around $75m, values the biosimilars unit at $4.17bn.
Mylan And Biocon Launch Semglee Insulin Glargine In US
Mylan and Biocon have launched their Semglee version of insulin glargine in the US, revealing pricing details for the Lantus rival. At the same time, the firms have offered an update on their attempts to have Semglee classified as a biosimilar as they seek an interchangeability designation.
Biocon Biologics Receives Further Investment As Value Hits $3.5bn
Biocon has received another influx of cash for its Biocon Biologics biosimilars arm, with a $30m investment from private equity group Tata Capital. Ahead of plans to realize $1bn of sales by its financial year ending March 2022, Biocon has been reorganizing and financing Biocon Biologics, with an initial public offering also on the cards by 2023.